A Longitudinal View of Bispecific Antibodies vs. CAR-T Therapies

Bispecifics vs. CAR-T: A Longitudinal Perspective

This case study illustrates how a leading global pharma organization leveraged AI-driven social intelligence to assess real-world perceptions of bispecific antibodies (bsAbs) compared to CAR T-cell therapies in the second-line LBCL treatment landscape. By capturing nuanced, real-time insights from digital channels, the organization gained early clarity on awareness gaps, sentiment drivers, and readiness for a potential U.S. launch.

Client

A leading global pharma organization sought to understand how bispecific antibodies (bsAbs) were being perceived compared to CAR T-cell therapies in the second-line (2L) LBCL treatment landscape.

Business Challenge

bsAbs were approved in the EU but not yet in the U.S., creating uncertainty around U.S. readiness.

Limited internal and real-world clinical data to inform positioning and education strategies.

The need to prepare early and strategically for a potential U.S. launch in a competitive treatment landscape.

Social media emerged as a critical signal source to capture real-time HCP and patient sentiment, awareness trends, and unmet needs.

Our Approach

Using Insight 360°, we applied an AI-driven social intelligence framework designed to capture nuance—not just volume.

We:

Curated conversations from 11+ digital platforms, including social media and medical forums.

Classified participants into HCPs, patients, and digital opinion leaders (DOLs).

Applied topic modelling to surface recurring themes, unmet needs, and evidence gaps.

Analysed sentiment strength and polarity to understand confidence vs. concern.

Anchored insights to the scientific and regulatory landscape—linking conversations to publications, trials, and approvals.

Impact

2,300+ high-quality conversations revealing real clinical sentiment.

500+ HCPs expressing distinct, often polarized views on bsAbs vs. CAR-T.

Previously unmapped DOLs shaping the narrative in meaningful ways.

A clear awareness gap around curability and cost, highlighting where education-not promotion-was needed.